论文部分内容阅读
目的探讨肿瘤相关钙信号转导蛋白2(Trop2)在晚期非小细胞肺癌(NSCLC)组织中的表达及其与预后的关系。方法应用免疫组化法检测Trop2在87例癌组织(A组,鳞癌组37例,腺癌组50例)和17例肺癌癌旁组织(B组)中的表达,分析其对预后的影响。结果 A组Trop2表达率为52.9%(46/87),B组几乎未见表达。鳞癌组Trop2表达高于腺癌组[67.6%(25/37)vs.42%(21/50)](P<0.05)。Trop2阴性表达组的中位数生存时间长于阳性表达组(17.25个月vs.13.27个月)(P<0.01),腺癌组尤为显著。结论肺癌组织Trop2表达与晚期NSCLC不良预后密切相关。
Objective To investigate the expression of Trop2 in advanced non-small cell lung cancer (NSCLC) and its relationship with prognosis. Methods Immunohistochemistry was used to detect the expression of Trop2 in 87 cases of cancer tissues (group A, 37 cases of squamous cell carcinoma, 50 cases of adenocarcinoma) and 17 cases of lung cancer adjacent tissues (group B), and its effect on prognosis . Results The expression rate of Trop2 in group A was 52.9% (46/87), but it was almost not seen in group B. The expression of Trop2 in squamous cell carcinoma was higher than that in adenocarcinoma [67.6% (25/37) vs.42% (21/50)] (P <0.05). The median survival time of Trop2 negative expression group was longer than that of positive expression group (17.25 months vs.13.27 months) (P <0.01), especially in adenocarcinoma group. Conclusion The expression of Trop2 in lung cancer is closely related to the poor prognosis of advanced NSCLC.